Standardized Treatment of Pulmonary exacerbations (STOP) study: Physician treatment practices and outcomes for individuals with cystic fibrosis with pulmonary exacerbations

Natalie E. West, Valeria V. Beckett, Raksha Jain, Don B. Sanders, Jerry A. Nick, Sonya L. Heltshe, Elliott C. Dasenbrook, Donald R. VanDevanter, George M. Solomon, Christopher H. Goss, Patrick A. Flume

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Background: Pulmonary exacerbations (PEx) are associated with increased morbidity and mortality in individuals with CF. PEx management practices vary widely, and optimization through interventional trials could potentially improve outcomes. The object of this analysis was to evaluate current physician treatment practices and patient outcomes for PEx. Methods: The Standardized Treatment of Pulmonary exacerbations (STOP) observational study enrolled 220 participants ≥. 12. years old admitted to the hospital for PEx at 11 U.S. CF centers. Spirometry and daily symptom scores were collected during the study. Physicians were surveyed on treatment goals and their management practices were observed. Treatment outcomes were compared to stated goals. Results: The mean (SD) duration of IV antibiotic treatment was 15.9 (6.0) days. Those individuals with more severe lung disease (<50% FEV1) were treated nearly two days longer than those with >50% FEV1. Physician-reported FEV1 improvement goals were 10% (95% CI: 5%, 14%) lower for patients with 6-month baseline FEV1 ≤50% predicted compared with those with 6-month baseline FEV1 >50% predicted. There were clinically and statistically significant improvements in symptoms from the start of IV antibiotic treatment to the end of IV antibiotic treatment and 28days after the start of treatment. The mean absolute increase in FEV1 from admission was 9% predicted at end of IV antibiotic treatment, and 7% predicted at day 28. Only 39% fully recovered lost lung function, and only 65% recovered at least 90% of lost lung function. Treatment was deemed successful by 84% of clinicians, although 6-month baseline FEV1 was only recovered in 39% of PEx. Conclusions: In this prospective observational study of PEx, treatment regimens and durations showed substantial variation. A significant proportion of patients did not reach physician's treatment goals, yet treatment was deemed successful.

Original languageEnglish (US)
JournalJournal of Cystic Fibrosis
DOIs
StateAccepted/In press - Sep 30 2016

Fingerprint

Cystic Fibrosis
Physicians
Lung
Therapeutics
Anti-Bacterial Agents
Practice Management
Observational Studies
Spirometry
Lung Diseases
Prospective Studies
Morbidity

Keywords

  • Antibiotic therapy
  • Cystic fibrosis
  • Physician treatment practices
  • Pulmonary exacerbations

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Pulmonary and Respiratory Medicine

Cite this

Standardized Treatment of Pulmonary exacerbations (STOP) study : Physician treatment practices and outcomes for individuals with cystic fibrosis with pulmonary exacerbations. / West, Natalie E.; Beckett, Valeria V.; Jain, Raksha; Sanders, Don B.; Nick, Jerry A.; Heltshe, Sonya L.; Dasenbrook, Elliott C.; VanDevanter, Donald R.; Solomon, George M.; Goss, Christopher H.; Flume, Patrick A.

In: Journal of Cystic Fibrosis, 30.09.2016.

Research output: Contribution to journalArticle

West, Natalie E. ; Beckett, Valeria V. ; Jain, Raksha ; Sanders, Don B. ; Nick, Jerry A. ; Heltshe, Sonya L. ; Dasenbrook, Elliott C. ; VanDevanter, Donald R. ; Solomon, George M. ; Goss, Christopher H. ; Flume, Patrick A. / Standardized Treatment of Pulmonary exacerbations (STOP) study : Physician treatment practices and outcomes for individuals with cystic fibrosis with pulmonary exacerbations. In: Journal of Cystic Fibrosis. 2016.
@article{363ed3c2585d40f0b876047db1a4b74d,
title = "Standardized Treatment of Pulmonary exacerbations (STOP) study: Physician treatment practices and outcomes for individuals with cystic fibrosis with pulmonary exacerbations",
abstract = "Background: Pulmonary exacerbations (PEx) are associated with increased morbidity and mortality in individuals with CF. PEx management practices vary widely, and optimization through interventional trials could potentially improve outcomes. The object of this analysis was to evaluate current physician treatment practices and patient outcomes for PEx. Methods: The Standardized Treatment of Pulmonary exacerbations (STOP) observational study enrolled 220 participants ≥. 12. years old admitted to the hospital for PEx at 11 U.S. CF centers. Spirometry and daily symptom scores were collected during the study. Physicians were surveyed on treatment goals and their management practices were observed. Treatment outcomes were compared to stated goals. Results: The mean (SD) duration of IV antibiotic treatment was 15.9 (6.0) days. Those individuals with more severe lung disease (<50{\%} FEV1) were treated nearly two days longer than those with >50{\%} FEV1. Physician-reported FEV1 improvement goals were 10{\%} (95{\%} CI: 5{\%}, 14{\%}) lower for patients with 6-month baseline FEV1 ≤50{\%} predicted compared with those with 6-month baseline FEV1 >50{\%} predicted. There were clinically and statistically significant improvements in symptoms from the start of IV antibiotic treatment to the end of IV antibiotic treatment and 28days after the start of treatment. The mean absolute increase in FEV1 from admission was 9{\%} predicted at end of IV antibiotic treatment, and 7{\%} predicted at day 28. Only 39{\%} fully recovered lost lung function, and only 65{\%} recovered at least 90{\%} of lost lung function. Treatment was deemed successful by 84{\%} of clinicians, although 6-month baseline FEV1 was only recovered in 39{\%} of PEx. Conclusions: In this prospective observational study of PEx, treatment regimens and durations showed substantial variation. A significant proportion of patients did not reach physician's treatment goals, yet treatment was deemed successful.",
keywords = "Antibiotic therapy, Cystic fibrosis, Physician treatment practices, Pulmonary exacerbations",
author = "West, {Natalie E.} and Beckett, {Valeria V.} and Raksha Jain and Sanders, {Don B.} and Nick, {Jerry A.} and Heltshe, {Sonya L.} and Dasenbrook, {Elliott C.} and VanDevanter, {Donald R.} and Solomon, {George M.} and Goss, {Christopher H.} and Flume, {Patrick A.}",
year = "2016",
month = "9",
day = "30",
doi = "10.1016/j.jcf.2017.04.003",
language = "English (US)",
journal = "Journal of Cystic Fibrosis",
issn = "1569-1993",
publisher = "Elsevier",

}

TY - JOUR

T1 - Standardized Treatment of Pulmonary exacerbations (STOP) study

T2 - Physician treatment practices and outcomes for individuals with cystic fibrosis with pulmonary exacerbations

AU - West, Natalie E.

AU - Beckett, Valeria V.

AU - Jain, Raksha

AU - Sanders, Don B.

AU - Nick, Jerry A.

AU - Heltshe, Sonya L.

AU - Dasenbrook, Elliott C.

AU - VanDevanter, Donald R.

AU - Solomon, George M.

AU - Goss, Christopher H.

AU - Flume, Patrick A.

PY - 2016/9/30

Y1 - 2016/9/30

N2 - Background: Pulmonary exacerbations (PEx) are associated with increased morbidity and mortality in individuals with CF. PEx management practices vary widely, and optimization through interventional trials could potentially improve outcomes. The object of this analysis was to evaluate current physician treatment practices and patient outcomes for PEx. Methods: The Standardized Treatment of Pulmonary exacerbations (STOP) observational study enrolled 220 participants ≥. 12. years old admitted to the hospital for PEx at 11 U.S. CF centers. Spirometry and daily symptom scores were collected during the study. Physicians were surveyed on treatment goals and their management practices were observed. Treatment outcomes were compared to stated goals. Results: The mean (SD) duration of IV antibiotic treatment was 15.9 (6.0) days. Those individuals with more severe lung disease (<50% FEV1) were treated nearly two days longer than those with >50% FEV1. Physician-reported FEV1 improvement goals were 10% (95% CI: 5%, 14%) lower for patients with 6-month baseline FEV1 ≤50% predicted compared with those with 6-month baseline FEV1 >50% predicted. There were clinically and statistically significant improvements in symptoms from the start of IV antibiotic treatment to the end of IV antibiotic treatment and 28days after the start of treatment. The mean absolute increase in FEV1 from admission was 9% predicted at end of IV antibiotic treatment, and 7% predicted at day 28. Only 39% fully recovered lost lung function, and only 65% recovered at least 90% of lost lung function. Treatment was deemed successful by 84% of clinicians, although 6-month baseline FEV1 was only recovered in 39% of PEx. Conclusions: In this prospective observational study of PEx, treatment regimens and durations showed substantial variation. A significant proportion of patients did not reach physician's treatment goals, yet treatment was deemed successful.

AB - Background: Pulmonary exacerbations (PEx) are associated with increased morbidity and mortality in individuals with CF. PEx management practices vary widely, and optimization through interventional trials could potentially improve outcomes. The object of this analysis was to evaluate current physician treatment practices and patient outcomes for PEx. Methods: The Standardized Treatment of Pulmonary exacerbations (STOP) observational study enrolled 220 participants ≥. 12. years old admitted to the hospital for PEx at 11 U.S. CF centers. Spirometry and daily symptom scores were collected during the study. Physicians were surveyed on treatment goals and their management practices were observed. Treatment outcomes were compared to stated goals. Results: The mean (SD) duration of IV antibiotic treatment was 15.9 (6.0) days. Those individuals with more severe lung disease (<50% FEV1) were treated nearly two days longer than those with >50% FEV1. Physician-reported FEV1 improvement goals were 10% (95% CI: 5%, 14%) lower for patients with 6-month baseline FEV1 ≤50% predicted compared with those with 6-month baseline FEV1 >50% predicted. There were clinically and statistically significant improvements in symptoms from the start of IV antibiotic treatment to the end of IV antibiotic treatment and 28days after the start of treatment. The mean absolute increase in FEV1 from admission was 9% predicted at end of IV antibiotic treatment, and 7% predicted at day 28. Only 39% fully recovered lost lung function, and only 65% recovered at least 90% of lost lung function. Treatment was deemed successful by 84% of clinicians, although 6-month baseline FEV1 was only recovered in 39% of PEx. Conclusions: In this prospective observational study of PEx, treatment regimens and durations showed substantial variation. A significant proportion of patients did not reach physician's treatment goals, yet treatment was deemed successful.

KW - Antibiotic therapy

KW - Cystic fibrosis

KW - Physician treatment practices

KW - Pulmonary exacerbations

UR - http://www.scopus.com/inward/record.url?scp=85018192527&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85018192527&partnerID=8YFLogxK

U2 - 10.1016/j.jcf.2017.04.003

DO - 10.1016/j.jcf.2017.04.003

M3 - Article

C2 - 28457954

AN - SCOPUS:85018192527

JO - Journal of Cystic Fibrosis

JF - Journal of Cystic Fibrosis

SN - 1569-1993

ER -